On July 20, 2012, the U.S. FDA granted accelerated approval to carfilzomib injection for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. See full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications.